A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
| 대상 질환 | Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | University of Iowa |
| 상태 | 완료 |
| 참여자 수 | 40 명 |
| 중재(약물) | Gemcitabine, nab-paclitaxel, Pharmacological ascorbate |
| 시작일 | 2018년 11월 28일 |
| 완료일 | 2024년 8월 26일 |
| 결과 공개일 | 2026년 7월 23일 |
요약
This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate in addition to the standard treatment).
Overall Survival
| Ascorbate Group | 16 months |
|---|---|
| Control | 8.3 months |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group